Richard D. Baird

Richard D. Baird

Auto-generated profile, based on publicly available information

Richard D. Baird

Department of Oncology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2017 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
JWJonathan Wan
Jonathan Wan
CMCharles Massie
Charles Massie
JGJavier Garcia-Corbacho
Javier Garcia-Corbacho
FMFlorent Mouliere
Florent Mouliere
JBJames D. Brenton
James D. Brenton
NRNitzan Rosenfeld
Nitzan Rosenfeld

7 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FMFlorent Mouliere
Florent Mouliere
DCDineika Chandrananda
Dineika Chandrananda
APAnna M. Piskorz
Anna M. Piskorz
EMElizabeth K. Moore
Elizabeth K. Moore
JMJames Morris
James Morris
NRNitzan Rosenfeld
Nitzan Rosenfeld
Selective sequencing or in silico analysis for differences in DNA fragment size can improve the detection of circulating tumor DNA.

10 December 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TYTimothy A. Yap
Timothy A. Yap
LYLi Yan
Li Yan
APAmita Patnaik
Amita Patnaik
IFIvy Fearen
Ivy Fearen
DODavid Olmos
David Olmos
ATAnthony W. Tolcher
Anthony W. Tolcher
Purpose: AKT signaling is frequently deregulated in human cancers. MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclinical models. A phase I study of MK-2206 was conducted to investigate its safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics (PDs), and preliminary antitumor efficacy.Patients and Methods: Patients with advanced solid tumors received MK-2206 on alternate days. Paired tumor biopsies were mandated at the MTD for biomarker studies. PD studies incorporated tumor and hair follicle analyses, and putative predictive biomarker studies included tumor somatic mutation analyses and immunohistochemistry for phosphatase and tensin homolog (PTEN) loss.Results: Thirty-three patients received MK-2206 at 30, 60, 75, or 90 mg on alternate days. Dose-limiting toxicities included skin rash and stomatitis, establishing the MTD at 60 mg. Drug-related toxicities included skin rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycemia (21.2%), and diarrhea (21.2%). PKs (area under the concentration-time curve from 0 to 48 hours and maximum measured plasma concentration) were dose proportional. Phosphorylated serine 473 AKT declined in all tumor biopsies assessed (P = .015), and phosphorylated threonine 246 proline-rich AKT substrate 40 was suppressed in hair follicles at 6 hours (P = .008), on days 7 (P = .028) and 15 (P = .025) with MK-2206; reversible hyperglycemia and increases in insulin c-peptide were also observed, confirming target modulation. A patient with pancreatic adenocarcinoma (PTEN loss; KRAS G12D mutation) treated at 60 mg on alternate days experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements. Two patients with pancreatic neuroendocrine tumors had minor tumor responses.Conclusion: MK-2206 was well tolerated, with evidence of AKT signaling blockade. Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.

1 August 2013 in The Lancet Oncology
Verified
Journal Article
Closed access
Shahneen K. SandhuShahneen K. Sandhu
Shahneen K. Sandhu
WSWilliam R Schelman
William R Schelman
GWGeorge Wilding
George Wilding
Victor MorenoVictor Moreno
Victor Moreno
RBRichard D Baird
Richard D Baird
RWRobert M Wenham
Robert M Wenham

1 September 2016 in Cell
Verified
Journal Article
Open access
ABAlejandra Bruna
Alejandra Bruna
OROscar M. Rueda
Oscar M. Rueda
WGWendy Greenwood
Wendy Greenwood
ABAnkita Sati Batra
Ankita Sati Batra
MCMaurizio Callari
Maurizio Callari
CCCarlos Caldas
Carlos Caldas
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the morphological and molecular characteristics of the originating tumor are preserved through passaging in the mouse. An integrated platform combining in vivo maintenance of these PDTXs along with short-term cultures of PDTX-derived tumor cells (PDTCs) was optimized. Remarkably, the intra-tumor genomic clonal architecture present in the originating breast cancers was mostly preserved upon serial passaging in xenografts and in short-term cultured PDTCs. We assessed drug responses in PDTCs on a high-throughput platform and validated several ex vivo responses in vivo. The biobank represents a powerful resource for pre-clinical breast cancer pharmacogenomic studies (http://caldaslab.cruk.cam.ac.uk/bcape), including identification of biomarkers of response or resistance.

10 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PSPeter Schmid
Peter Schmid
JAJacinta Abraham
Jacinta Abraham
SCStephen Chan
Stephen Chan
DWDuncan Wheatley
Duncan Wheatley
ABAdrian Murray Brunt
Adrian Murray Brunt
NTNicholas C. Turner
Nicholas C. Turner
PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS: This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/ AKT1/ PTEN alterations, tumor response, and safety. RESULTS: Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/ AKT1/ PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION: Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/ AKT1/ PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.